TMCnet News
Global Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) Therapeutics Pipeline Review, H1 2016 - Research and MarketsResearch and Markets has announced the addition of the "Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) - Pipeline Review, H1 2016" report to their offering. Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) Histone deacetylase 3 is an enzyme encoded by the HDAC3 gene. Histone deacetylation gives a tag (News - Alert) for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. It participates in the regulation of transcription through its binding with the zinc-finger transcription factor YY1. This protein can also down-regulate p53 function and thus modulate cell growth and apoptosis. Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) pipeline Target (News - Alert) constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 2, 1, 3 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/gghz2x/histone Related Topics: Pharmaceuticals
View source version on businesswire.com: http://www.businesswire.com/news/home/20160829005770/en/ |
